Medical Reform Negative "domestic Demand" Engine Pharmaceutical Companies To The College Entrance
As "domestic demand" engine strong start, the medical and health sector is bound to be a crucial one hot market. Against this background, new Medical Reform Program role to play Pharmaceutical Industry Might face more competition and depth adjustment.
11 5, the State Council executive meeting, study and plan to further expand domestic demand to promote fast and steady economic growth of 10 measures to accelerate the development of health care ranked among the requirements, and infrastructure construction, affordable housing and financial industries together constitute the mainstay of China's economic stability and industry. Directly related with the 10 measures, the next two years the state will add 4 trillion yuan investment, which is equivalent to total fixed asset investment in 2007 to 29.2%. The context of medical reform Pharmaceutical market Seems to be of interest.
Frank Gong, managing director of Morgan Chase has talked about China's steady economic growth in the policy premise that the Chinese government to smooth the economy can invest in infrastructure, strategic policy support and financial subsidies to do something. The strategic policies that include education, health care and social security.
"The Chinese government investment in recent years to strengthen health and improve the health care system, efforts to help speed up the release of the pharmaceutical industry's domestic demand, while the recently released new medical reform and other measures to deepen the medical and health system will further consolidate this a trend. "Xinhua Finance entitled" Prospects for China's pharmaceutical industry, the credit, "the report said. In addition, because investment in medical and health services can not only pull the output value of pharmaceutical industry, but also to protect family health care costs by reducing the boost consumer confidence in other sectors, thus stimulating social and economic capacity may be doubled overall, with the data, said per 100 million yuan on medical protection of the financial investment community can pull the total amount spent one billion yuan.
"Large global pharmaceutical company is expanding its operations in the Chinese market, which shows China's increasing purchasing power and coverage of broader health care system has brought an important opportunity. But at the same time, a number of business opportunities in China the complexity of the forcing enterprises to pursue flexible and innovative business model. "safety is always the Eastern pharmaceutical industry managing partner, said Li Yongguang.
Ernst & Young has 15 operating in China on the global leader in system Pharmaceutical companies 40 senior industry executives surveyed, the results show that, despite the global financial crisis on China's real economy and the consumer market is still difficult to accurately determine the extent, but the next few years, China will remain the most important pharmaceutical market growth 1, and China's current medical needs are increasing.
Although the macro-direction is clear, but in the midst of which the future prospects of pharmaceutical companies still grew by nearly half and half. At the recent situation of Chinese medicine for 30 years will be an interview process, a number of pharmaceutical companies, said its 2008 profits had been affected by macroeconomic impact of lower than expected. To produce anti-tumor drugs such as cardiovascular disease mainly of large integrated pharmaceutical companies with the Jubilee Qilu Pharmaceutical Vice Chairman Ma introduced to the Shanghai Securities News, the first 10 months of this year, the company exports pharmaceutical and contract prices dropped about 20% of sales . Although highly promising forward market, but by the impact of uncertainty, expected next year group sales have been down. More of a Traditional Chinese medicine Company executives said that some main Chinese caterpillar fungus, etc. Traditional Chinese medicine Nourishment of the corporate earnings have been down more than 40%.
With medical reform plan is still in the process of intense debate, including essential drugs system and other new regulations will affect pharmaceutical companies in the extent to which the structure and development are still variable. "China is a drug support system of medicine evolved over the years, and involve the interests of deep-rooted party, completely change the need for state financial investment is too large, but once the investment is not in place or the wrong direction, health care reform would be counterproductive." A medicine experts said. Among them, the system may lead to essential drugs essential drugs on the market battle for qualification one of the greatest concern.
11 5, the State Council executive meeting, study and plan to further expand domestic demand to promote fast and steady economic growth of 10 measures to accelerate the development of health care ranked among the requirements, and infrastructure construction, affordable housing and financial industries together constitute the mainstay of China's economic stability and industry. Directly related with the 10 measures, the next two years the state will add 4 trillion yuan investment, which is equivalent to total fixed asset investment in 2007 to 29.2%. The context of medical reform Pharmaceutical market Seems to be of interest.
Frank Gong, managing director of Morgan Chase has talked about China's steady economic growth in the policy premise that the Chinese government to smooth the economy can invest in infrastructure, strategic policy support and financial subsidies to do something. The strategic policies that include education, health care and social security.
"The Chinese government investment in recent years to strengthen health and improve the health care system, efforts to help speed up the release of the pharmaceutical industry's domestic demand, while the recently released new medical reform and other measures to deepen the medical and health system will further consolidate this a trend. "Xinhua Finance entitled" Prospects for China's pharmaceutical industry, the credit, "the report said. In addition, because investment in medical and health services can not only pull the output value of pharmaceutical industry, but also to protect family health care costs by reducing the boost consumer confidence in other sectors, thus stimulating social and economic capacity may be doubled overall, with the data, said per 100 million yuan on medical protection of the financial investment community can pull the total amount spent one billion yuan.
"Large global pharmaceutical company is expanding its operations in the Chinese market, which shows China's increasing purchasing power and coverage of broader health care system has brought an important opportunity. But at the same time, a number of business opportunities in China the complexity of the forcing enterprises to pursue flexible and innovative business model. "safety is always the Eastern pharmaceutical industry managing partner, said Li Yongguang.
Ernst & Young has 15 operating in China on the global leader in system Pharmaceutical companies 40 senior industry executives surveyed, the results show that, despite the global financial crisis on China's real economy and the consumer market is still difficult to accurately determine the extent, but the next few years, China will remain the most important pharmaceutical market growth 1, and China's current medical needs are increasing.
Although the macro-direction is clear, but in the midst of which the future prospects of pharmaceutical companies still grew by nearly half and half. At the recent situation of Chinese medicine for 30 years will be an interview process, a number of pharmaceutical companies, said its 2008 profits had been affected by macroeconomic impact of lower than expected. To produce anti-tumor drugs such as cardiovascular disease mainly of large integrated pharmaceutical companies with the Jubilee Qilu Pharmaceutical Vice Chairman Ma introduced to the Shanghai Securities News, the first 10 months of this year, the company exports pharmaceutical and contract prices dropped about 20% of sales . Although highly promising forward market, but by the impact of uncertainty, expected next year group sales have been down. More of a Traditional Chinese medicine Company executives said that some main Chinese caterpillar fungus, etc. Traditional Chinese medicine Nourishment of the corporate earnings have been down more than 40%.
With medical reform plan is still in the process of intense debate, including essential drugs system and other new regulations will affect pharmaceutical companies in the extent to which the structure and development are still variable. "China is a drug support system of medicine evolved over the years, and involve the interests of deep-rooted party, completely change the need for state financial investment is too large, but once the investment is not in place or the wrong direction, health care reform would be counterproductive." A medicine experts said. Among them, the system may lead to essential drugs essential drugs on the market battle for qualification one of the greatest concern.
About the Author:
I am a professional writer from China Bags Wholesale, which contains a great deal of information about crafts wind chime , china panda gold coin, welcome to visit!
Author: dfjyj